The global immuno oncology assays market is witnessing strong growth due to the increasing adoption of immunotherapy and the rising demand for advanced cancer diagnostics. These assays are essential for tumor profiling, biomarker detection, and evaluating patient responses to therapies, making them a crucial component in precision medicine and oncology research.

Market Size & Forecast

The global immuno oncology assays market was valued at USD 6.08 billion in 2025

The market is projected to grow from USD 6.89 billion in 2026 to USD 16.85 billion by 2034

It is expected to exhibit a CAGR of 11.8% during the forecast period (2026–2034)

Emerging Trends

The market is rapidly evolving with the adoption of advanced technologies such as next-generation sequencing (NGS), multiplex assays, and spatial biology tools. These innovations are improving the understanding of tumor microenvironments and enabling more precise biomarker identification. There is a growing shift toward personalized medicine, where immuno oncology assays are increasingly used to tailor treatments based on individual patient profiles. Additionally, pharmaceutical companies are leveraging these assays in clinical trials to enhance drug development and improve therapeutic outcomes. The integration of automation and digital data analysis is also streamlining laboratory workflows and increasing efficiency.

View More Information: https://www.fortunebusinessinsights.com/immuno-oncology-assays-market-111498

Major Key Players in Immuno Oncology Assays Market

• Thermo Fisher Scientific Inc. (U.S.)
• Hoffmann-La Roche Ltd (Switzerland)
• Illumina, Inc.(U.S.)
• Agilent Technologies, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Danaher (U.S.)
• Merck KGaA (Germany)
• QIAGEN (Netherlands)
• Revvity (U.S.)
• 10x Genomics (U.S.)

Market Segmentation (As per Source)

By Product

• Instrument
• Consumables

By Technology

• Immunoassay
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Immunohistochemistry (IHC)
• Others

By Indication

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Others

By End-user

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Others

Regional Analysis

North America leads the immuno oncology assays market due to advanced healthcare infrastructure, high adoption of innovative cancer therapies, and strong presence of key industry players. Europe holds a substantial share, supported by extensive research activities and well-established clinical frameworks. The Asia Pacific region is expected to witness the fastest growth, driven by increasing cancer prevalence, rising healthcare investments, and expanding research capabilities in countries such as China, India, and Japan. Meanwhile, Latin America and the Middle East & Africa are gradually emerging markets, supported by improving healthcare infrastructure and growing focus on cancer diagnostics.

Growth Drivers

The market growth is primarily driven by the rising global burden of cancer and the increasing adoption of immunotherapy treatments. The growing emphasis on precision medicine and the need for accurate companion diagnostics are significantly boosting the demand for immuno oncology assays. Additionally, the expansion of pharmaceutical and biotechnology industries, along with a growing number of clinical trials, is accelerating market growth. Continuous technological advancements, including improved sensitivity and accuracy of assays, are further supporting the expansion of the market.

Request a Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immuno-oncology-assays-market-111498

About Us (Fortune Business Insights)

Fortune Business Insights is a global market research and consulting firm that delivers reliable data and actionable insights to organizations worldwide. The company specializes in providing comprehensive market intelligence through detailed research reports that support strategic decision-making.